CONSTITUENT REPORT
Longifolene
Longifolene is a tricyclic sesquiterpene hydrocarbon associated with pine, cedarwood, and vetiver-type aromatic materials. The strongest public evidence available here supports identity, fragrance-safety review status, and a modest preclinical literature that includes cell-based anti-inflammatory work and exploratory cytotoxicity testing. That makes longifolene suitable for chemistry-led archive copy with carefully labeled preclinical findings, but not for human therapeutic claims.
Chemical identity and composition
PubChem identifies longifolene as C15H24 and a tricyclic sesquiterpene hydrocarbon. Synonym data connect it with the older name junipene, and archive oil context shows it as a quantified minor constituent in the current cedar-wood-thuja-china record at 4.2%. The accessible literature also describes longifolene as a fragrance-material feedstock and as a naturally occurring terpene in pine- and vetiver-related matrices.
Aroma and practical use
- Use the recorded woody, resinous, pine-like, dry, resin descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Review the flagged use concerns across every contributing oil and the selected dilution.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 2021 Biomolecules paper reported that longifolene was among the most active single constituents from Pinus koraiensis wood oil in reducing IL-4, IL-13, and beta-hexosaminidase signals in LPS-stimulated RBL-2H3 cells, with effects described as comparable to dexamethasone in that assay system.
A 2021 Biomolecules paper reported that longifolene was among the most active single constituents from Pinus koraiensis wood oil in reducing IL-4, IL-13, and beta-hexosaminidase signals in LPS-stimulated RBL-2H3 cells, with effects described as comparable to dexamethasone in that assay system.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2022 Molecules study isolated longifolene from Chrysopogon zizanioides and reported IC50 values of 78.64 microg/mL against DU-145 prostate cancer cells and 88.92 microg/mL against SCC-29B oral cancer cells, with lower toxicity in Vero cells at 246.3 microg/mL.
A 2022 Molecules study isolated longifolene from Chrysopogon zizanioides and reported IC50 values of 78.64 microg/mL against DU-145 prostate cancer cells and 88.92 microg/mL against SCC-29B oral cancer cells, with lower toxicity in Vero cells at 246.3 microg/mL.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2019 RIFM fragrance ingredient safety assessment shows that longifolene has been reviewed within the modern fragrance-safety literature, giving it better safety-documentation footing than many obscure sesquiterpenes.
A 2019 RIFM fragrance ingredient safety assessment shows that longifolene has been reviewed within the modern fragrance-safety literature, giving it better safety-documentation footing than many obscure sesquiterpenes.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
Use concerns and concentration limits
Sensitization concernFlagged
Flagged in the constituent reference; assess the source, route and finished-product concentration.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
A recorded constituent reference, not a recommended oil dilution. Product category, source applicability and all contributing oils must be checked before use.
recorded reference · IFRA Standard, Longifolene (Amendment 49, 2020), Category 5A/5B leave-on body lotion/face moisturizer maximum = 0.38%, driven by dermal sensitization (RIFM WoE NESIL 3500 microg/cm2); RIFM fragrance ingredient safety assessment, CAS 475-20-7 (Api et al., 2019)Longifolene has a dedicated RIFM fragrance safety assessment, which is more safety-context coverage than many minor terpenes receive, but this pass did not verify a simple public dermal-limit number from that review.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
No direct public citation is attached to this entry.
The constituent-level activity literature reviewed here is entirely preclinical, so consumer-facing copy should avoid anti-inflammatory or anticancer benefit claims.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
These are research candidates recorded in the interaction matrix. They do not add a proven-amplification bonus to the score.
gamma-TerpineneAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro mechanistic · antioxidant
No source citation attached.
Read gamma-Terpinene report →How the effects were investigated
il 4 and il 13 downregulation in rbl 2h3 cells
In an RBL-2H3 cell model, longifolene was one of the tested pine-oil constituents that reduced IL-4 and IL-13 expression relative to LPS-stimulated controls.
This experimental finding does not establish benefit, dose or safety in people using this blend.
No direct public citation is attached to this entry.
beta hexosaminidase release reduction
The same cell-based anti-inflammatory study found that longifolene contributed to suppression of beta-hexosaminidase release, supporting an anti-allergic or mast-cell-related laboratory mechanism signal.
This experimental finding does not establish benefit, dose or safety in people using this blend.
No direct public citation is attached to this entry.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (5)
- No human clinical evidence for isolated longifolene was verified in this pass.
- The anti-inflammatory and cytotoxic findings are limited to laboratory models and should not be translated into medical claims.
- Constituent-specific leave-on dermal ceiling is now confirmed via the IFRA Standard and RIFM safety assessment (Category 5A/5B leave-on body/face products = 0.38%); this pass did not find data indicating longifolene functions as a dermal penetration enhancer for other ingredients.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.
- Interaction candidates lack an attached source citation and remain unqualified.